TL;DR
Chikungunya virus (CHIKV) causes a debilitating, often chronic, febrile illness with no approved treatments. This review comprehensively surveys current antiviral research, detailing strategies for identifying small-molecule inhibitors targeting viral proteins and host factors, and highlighting promising candidates for future drug development.
What Problem Does This Paper Address?
Chikungunya fever (CHIKF), caused by the CHIKV, has re-emerged globally, leading to widespread epidemics characterized by severe joint pain and myalgia. A significant challenge is that many patients develop a chronic, painful stage that can persist for months or years. Crucially, there are currently no licensed antiviral drugs or vaccines available for CHIKF, leaving supportive care (like NSAIDs) as the only treatment option. This lack of effective therapeutics necessitates the urgent development of potent antiviral agents to combat this significant public health threat.
Methods
This review synthesizes findings from various approaches used to identify antiviral compounds against CHIKV. These include:
- Cell-based high-throughput screening (HTS): This standard method uses the virus-induced cytopathic effect (CPE) as a readout to simultaneously assess antiviral activity and cytotoxicity.
- Computational methods:
- Rational structure-based drug design: Utilizes known crystal structures or homology models of viral and host proteins to design inhibitors.
- In silico screening (virtual screening): Employs computer models to rapidly screen large compound libraries for potential drug candidates.
- Structure-activity relationship (SAR) assays: Used to optimize the identified lead compounds.
- Resistance selection assays: Performed in cell-based assays to identify the target protein of a compound and gain insights into viral pathways.
- Drug repurposing: Investigating already approved drugs for new therapeutic uses against CHIKV.
The review also discusses strategies for identifying both viral targets (e.g., viral proteins essential for replication) and host-directed targets (proviral host factors that the virus relies on).
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Dual Targeting Strategy: The paper emphasizes the potential of targeting either viral proteins directly or host factors that CHIKV relies on for replication. Targeting host factors could lead to broad-spectrum antivirals, but may also carry a higher risk of side effects.
- Importance of In Silico Validation: While computational methods are powerful for identifying potential drug candidates, the paper stresses the critical need for subsequent in vitro and in vivo validation, as in silico predictions don't always correlate with experimental results.
- Chronic Pain as a Major Challenge: The persistence of severe joint pain and myalgia in a significant portion of infected patients highlights the need for treatments that can address not just acute infection but also long-term sequelae.
- Drug Resistance is a Concern: CHIKV's ability to mutate and develop resistance to antiviral therapies is a significant hurdle. The review suggests that combination therapies or drugs with multiple targets could mitigate this issue.
- Repurposing Approved Drugs: Given the urgent need for treatments, repurposing existing FDA-approved drugs offers a faster and safer route to clinical evaluation, as their safety profiles are already well-established.
Key Results
The review presents extensive tables summarizing numerous compounds tested against CHIKV. While specific quantitative results vary widely due to different experimental setups, key findings include:
- Viral Protein Inhibitors: Numerous compounds have been identified that target various CHIKV proteins, including E2, nsP1, nsP2, nsP3, nsP4, and the capsid protein. For example, compounds like Arbidol and Suramin show activity against viral entry and membrane fusion, while others target non-structural proteins crucial for replication.
- Host Factor Inhibitors: A broad range of host factors have been identified as potential targets, including those involved in viral entry (e.g., pH regulation), lipid pathways, pyrimidine and purine synthesis, protein synthesis, cellular enzymes (hydrolases, kinases), cellular receptors, and immunomodulatory pathways.
- Promising Repurposed Drugs: Several FDA-approved drugs, such as Favipiravir, Sofosbuvir, Ribavirin, and Auranofin, have demonstrated antiviral activity against CHIKV in vitro and, in some cases, in vivo, showing reduced pathological signs and improved outcomes in animal models.
- In Vivo Efficacy Demonstrated: A subset of compounds has shown efficacy in animal models, reducing viral burden, inflammation, or mortality. For instance, Favipiravir demonstrated efficacy in a CHIKV-mouse model, preventing severe neurological disease.
Limitations and Future Work
The authors acknowledge several limitations:
- Early Stage of Development: Most identified antiviral compounds are still in the early stages of drug development, with activity primarily tested in vitro.
- Variability in Experimental Data: The values presented in the tables are not directly comparable due to differences in experimental setups, virus strains, and cell lines used across studies.
- Toxicity Concerns: Some promising compounds exhibit significant toxicity, requiring further optimization.
- Unclear Mechanisms: For many identified compounds, the precise mechanism of action remains unclear, necessitating further investigation.
Future work should focus on:
- Clinical Evaluation: Moving promising candidates from in vitro and in vivo studies to clinical trials.
- Mechanism of Action Elucidation: Thoroughly investigating the precise molecular targets and pathways affected by antiviral compounds.
- Addressing Drug Resistance: Developing strategies to overcome or prevent the emergence of drug-resistant CHIKV strains.
- Identifying Novel Targets: Continuing research into the CHIKV life cycle to uncover new, safe, and effective therapeutic targets.
- Combination Therapies: Exploring synergistic effects of combining different antiviral compounds or host-directed agents.
Summary updated